Tratamiento de la hipertensión arterial en la diabetes tipo 2: importancia de la selección terapéutica
DOI:
https://doi.org/10.31053/1853.0605.v62.n3.32473Palabras clave:
Hipertensión arterial, Diabetes tipo 2, Selección terapéuticaResumen
ANTECEDENTES: La hipertensión y la diabetes son las causas irias comunes de insuficiencia renal terminal en Argentina. Sobre 887 transplantes de órganos efectuados en el año 2004, correspondieron 577 a transplantes renales. En poblaciones urbanas y rurales argentinas la hipertensión tiene una prevalencia mas alta en diabéticos, siendo el tipo mas frecuente la hipertensión sistólica. Los estudios sobre la evolución se utilizan para estimar los puntos finales altamente significativos desde la perspectiva clínica. Ni ies tras conocimientos actuales sobre los efectos riel tratamiento de la hipertensión en la diabetes tipo 2 se fundan en los resultados obtenidos en estudios longitudinales randomizados. AMBITO: El presente trabajo, basado sobre una bósqiteda en el periodo 1990-2005 de la literatura MEDLINE, revisa los estudios randoinizados con el objetivo de determinar cuales son las mejores estrategias terapéuticas en esta asociación mórbida. La mayoría de los pacientes requieren dos a cuatro drogas antihipertensivas para enlentecer la progresión de daño de órganos nobles. La elección inicial de las drogas a utilizar debería fundarse sobre la presencia o no de complicaciones en órganos blanco. En aquellos pacientes sin evidencias de complicaciones, el objetivo primario es alcanzar niveles de PA <130/80 mm Hg, mas allá de las diferencias que existen entre las distintas clases de fármacos, mientras que en aquellos con afectaciones de órgano blanco se requiere mantener la PA en <120/75 mm Hg.
Descargas
Referencias
Simonson [)C. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care: 1988,11:821-7.
Burlando O, Sánchez RA, Ramos F'H, Mogensen CE, Zanchetti A., on behalf of the Latin American Experts Group. Latin American Consensus on diabetes mellitus and hypertension. J. Hypertens 2004, 22: 2229-41.
Gagliardino .J. Olivc E, Barragan H. Herimamidez R. Diabete mellitus and hypertension, clinical anci epiclemiological aspects in the population of La Plata. Medicina (Buenos Aires): 1995, 55: 421-30.
Sereday MS, Gonzalez C, Giorgini D. De Laredo L, Braguinsky J. Cobenas C, et al, Prevalence of diabetes, obesity, hypertension and hyperlipidemia in the central arca of Argentina. Diabetes Metab: 2004,30:335-9.
Feldstein CA, Arpa A. La hipertensión arterial como factor de riesgo en las complicaciones caí diovasculares de la diabetes mellitus. Rey Clin Española: 1992, 190: 243-8..
Hypertension in Diabetes Study Group. Hypertensión in diabetes study (HDS): 1. ['revalerice of hypertension in newly presenting type 2 diabetic patients and the associationi with risk factors for cardiovascular and diabetic complications. J.Hypertens: 1993,11:309 - 17.
Stas SN, El-Atat FA, Sowers JR. Pathogenesis of hyperteusion in diabetes. Rey Endocr Metab Disord; 2004, 5: 221-5.
Mancia U. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressurc reduction. Acta Diahetol: 2005.42 (Suppl 1): Sl7-25.
Ritz E: Hypertension in diabetic nephrupathy: prevention and treatment. Am l-Ieart J: 1993,19:1514-9.
Gerstein HC. Mann ,JF, Yi Q. Zinman E. Dmnneen SE, Hoogwerf B, el al. 1-JOPE Stody 1 nvestigators. Albuminuria and risk of cardiovascular events, death and heart failure in diahetic and nondiabetic individuals. JAMA; 2001.286: 421-6.
Norgaard K, Rasmussen E. Jensen T, Giese J, Feldt-Rasmussen B. Nature of elevated blood pressure in normoalhuminuric type 1 diabetic patients. Essential hypertension. Am .J. I-lypertens; 1993, 6: 830-6.
Valmadrid CT, Klein R. Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuniinuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med; 2000,160, 1093-100.
Farreras Valentí P, Rozinan C. Medicina Interna, Elsevier Madrid, 2004, p882. llaed. Ministerio de Salud Pública de la República Argentina. Dirección de Estadística e Información de Salud-Anuario 2003. ISSN 1668-9054.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National High Blood Pressure E d u ca ti o n Prograni Co o r dina ti ng Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Iligh Blood Pressure. The JNC 7 Report. JAMA; 2003,289:2560-72.
World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organisation (WFIO )/Internationa1 Society of Hypertension (lSH) statement on managerncnt of hypertension. J Hypertens:. 2003,21:1983-92.
Arauz-Pacheco C, Parrott MA, Raskin P American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care; 2003.26:S80-S82.
Adler Al, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ; 2000,321:412-9.
Arauz-Pacheco C, Parrott MA, Raskin E The treatment of hypertension in adult patients with diabetes (Technical Review): Diabetes Care: 2002, 25: 134-47.
Svetkey LP Simons-Morton DG, Proschan MA, Sacks FM, Conlin PR, Harsha D. et al. Effect of the dietary approaches to stop hypertension and rcduced sodiurn intake on blood presssure control. J Clin Hypertens (Greenwich); 2004, 6:373-81.
Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiarnathi E, Kostis JB, et al. ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycernia: Antihypertensive and Lipid-Lowering Treatnient to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med: 2005,165:1401-9.
Rahman M, Pressel 5, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Renal outcomcs in high-risk hypertensive patients treated with an angiotensin-converting enzynie inhibitor or a calcium channel biocker vs a diuretic: a report froin the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch lntern Mcd: 2005, 165:936-46.
Kjeldsen SE, Julius 5, Brunner H, Hansson L, Henis M, Ekman S et al; VALUE Trial Group. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Press; 2001,10:83-91.
Julius 5, Kjeldsen SE, Weber M, Brunner lIR, Ekman S, Hansson L, et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens hased on valsartan or amlodipine: the VALUE randomized trial. Lancet: 2004,363:2022-31. Weber MA; Julius S, kjeldsen SE, Brunner HR, Ekman S, Hansson L., et al. Blood pressure dependent and independent effects of antihypertensive treatinent oil clinical events in the VALUE Trial. Lancet; 2004.363:2049-51.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ; 1998, 317: 713-20.
Lansson L, Lindholrn LFI, Niskanen L, Lanke J, Hedner T, Niklason A. et al. Effect of ACE inhihition compared with conventional therapy on cardiovascular morhiclity and mortality in hypertension: the Captopril Prevention Project (CAPPP). Lancet; 1999.353:611-6.
Niskarien L, Heclner T, Hasson L. Lanke J, Niklason A. CAPPP Study Group. Reduced cardiovascular morbidity arid mortality in hypertensive cliabetic patients on first-line therapy with an ACE inhibitor compared with a diureticilieta-blocker based trcatment reginlc: a subanaJysis of the Captopril Prevention Project. Diabetes Case; 2001,24:2091-6.
Estacio RO, Jeffers BW. Hiatt WR, Biggerstaff SL, Gifford N. Schrier RW. The effect of nisoldipirie as compared with enalapril oii cardiovascular outcornes in patients with noninsulin dependent diabetes and hypertension. N Engl J Mcd; 1998,338:645-52.
Tatti P Pahor M, Byington RP Di Mauro P Guarisco R, Strollo O., et al. Outcome results of the Fosinopril versus Anilodipine Cardiovascular Events Randomised Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care: 1998,21:597-603.
Ravid M, Brosch D, Levi Z, Bar-Dayan Y. Ravid D, Rachmani E. Use of enalapril to attenuate decline in renal function in norniotensive, norinoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled ti-¡al. Aun lntern Mcd; 1998, 128:982-8.
Heart Outcomes Prevention Evaluation Study lnvestigators. Effects of r ami p rl 1 on cardiovascular a n d microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet; 2000, 355: 253- 9.
Yusuf S. Slcight e Pogue 3, Bosch J. Davies R, Dagenais O. Effects of an angiotensin-converting enzymc inhibitor, rarnipril, oil cardiovascular events in high-risk patients. The lleart Outcornes Prevention Evaluation Study lnvestigators. N Engi J Mccl; 2000, 342:145-53.
Bcrl T, Hunsicker LG, Lewis JB. Pfeffer MA, Porush JC, Rouleau JL., et al. Cardiovascular outcomes in the Irbesartan Diahetic Nephropathv Trial of paticnts with type 2 diabetes and overt nephropathy. Anu lntern Mcd; 2003,138:542-9.
Bien ner BM, Cooper ME, de Zecuw D. Keane WE Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropatliy. N Engl J Mcd: 2001, 345:861-9.
Lindlholnl LI-!, Ibsen 11, Dahlof B, Devereux RB, Beevers O, de Paire U,et al. Cardiovascular morbiclity and mortality in patients with diabetes in the Losartan Intervenlion Por Endpoint reduction in hypertension stucly (LIFE): a ranclomizecl rial agai ns t a te 110101. Lance t: 2002,359:1004-10.
Moser M. Results of ALLIlAT. ls Ibis the final answer regardling initial ant!-hypertensive clrug therapy? Arcli lntern Mcd; 2003,163:1269-73. Dahlof B. Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Paire U, et al. Cardiovascular morbidlity and mortality in the Losartan Intervention Por End pOint reduction in hypertension study (LIFE): a randomized ti-¡al against atenolol. Lancet: 2002,359:995-1003. Siehenhofer A, Plauk 3, Florvath K, Berghold A, Sutton AJ, Sommer R. et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controllcd double-blind randlonlized trials. Diabet Mccl: 2004. 21:18-25
Marshall SM. Inhibition of the renin-angiotensin system: added value 01 reducing cardiovascular and renal risk? Diahet Mcd: 2004, 21:1-3. Barnett AH. Bain SC, Bouter P Karlberg B, Maclsbacl 5, Jerwell J. et al: Angiotelisin- Rece ptor hiockade versus converting-enzyme inhibition in type 2 diabetes ant! nephropatby. N Engl .1 Mcd: 2004, 351: 1952-61.
Scheen AJ. Similar reduction in new cases of type 2 diabetes with angiotcnsin recoptor biocker and ACE inhibitor: comparison of ineta-analyses of prospective randomisecl trials. Rey Med Liegc; 2005, 60: 424-8.
Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Manda G, Rosenthal T, et al. Morbidity and niortality in patients randoinized to double-blind treatment with a long-acting calcium-channel biocker or diuretic in the International Nifedipine GITS stucly: Intervention as a Goal in Hypertension Treatment (INSIGF1T). Lancet; 2000, 356:366-72.
Mancia G, Brown M. Castaigne A, de Leeuw P Palmer CR, Rosenthal T, ct al. Outcomes with nifedipine GITS or co-amiloridc in hypertensive diabetics and nondiabctics in intervention as a goal in hypertension (INSJGIIT). Hypertension 2003.41:431-6.
Hansson L. Hedner T, Lund-Johansen P Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality ja hypertension: the Nordic Diltiazem (NORDIL) Study. Lancet; 2000, 356:359-65. Black HR, Elliott WJ, Grandits G. Granibsch F Lucente T, White WB, et al. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) trial. JAMA; 2003,289:2073-82.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery discase. The International Vcrapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA; 2003,290:2805-16.
Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S. Rosenthal T. et al. Benefits and risks of more intensive blood pressure lowcring in hypertensive patients of the HOT study with clifferent risk profiles: does a J-shaped curve exist lo srnokers?. 3 Hypertens; 2003, 21(4):797-804.
Gress TW, Neito FJ, Shahar E, Wofford MR, Brancati FL. Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. New Engl 3 Mcd: 2000,342:905-12.
Liridholm LH, Hansson L. Ekbom T. Dahlof B. Lanke J, Linjer F.et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetie patients: results from the Swedish Trial in Oid patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens:. 2000,18:1671-5.
Julius 5, Majahalme S, Palatini E Antihypertensive treatment of patients with diabetes and hypertension. Am 3 Hypertens; 2001,14: 310 S-S6.
Agrawai R, Lichtental A, Milbredt C. Nebivolol, a selective beta-hlocker with vasoclilatating properties, exihits positive effects on glucose metabolism in hypertensive patients with diabetes. Am 3 Hypertens: 2001, 14 (Suppll): A 103.
Bristow MR, Gilbert EM, Abraham WT, Adams KF, F'owler MB, Hershberger RE, et al. Carvedilol produces close-related improvements in left ventricular function aoci survival in subjects with chronic heart failure. MOCHA Investigators. Circulation; 1996,94:2807-16.
Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs; 2005, 65:773-86.
Bakris GL, Williams M, Dworkin L. Elliott WJ, Epstein M, Toto R, et al. Preserving renal function la adults with hypertension and diabetes: a consensus approach. National Kidney F'ounciation Hypertension and Diabetes Executive Committecs Working Group. Am 3 Kidney Dis; 2000, 36:646-61.
Mogensen CE, Viberti GC, Halimi S, Ritz E, Ruilope L. Jermencly G, et al. Effect of low-dose perindopril / indapamicle on albuminuria in type 2 diabetes. The PREMIER study. Hypertension: 2003, 41: 1063-71
Mogensen CE, Neldain S. Tikkanen 1, Oren S. Viskoper R, Watts RW, et al. Randomized controlled trial of dual biockade of renin-angiotensin system in patients with hypertension, niicroalbumninuria, and non-insulin dependent diabetes:, the candesartan and lisinopril microalbuminuria (CALM) study. BMJ; 2000, 321: 1440-4
Pitt B. Byington RE Furberg CD, Hunninghake DB, Mancitti GB, Millet- ME.et al. Effect of alnlo(lipine oit the progression of atherosclerosis aiid the occurrence of clinical events. Circulation: 2000,102:1503-lo.
Heclblad B, Wikstrancl 3, Janzon L, Wedel H, Bergiund O. Low dose nietuprolol CRIXL and fluvastatin slow progression of carotici intima-media thickness: niain resulis from the Beta-blocker Cliolesterol.lowering Asymptoniatic Plaque Study ( I3CAPS) - Circulation 2001,103:1721-6.
Nissen SE, Tuzcu EM, Libby R Brown BG, Ganz P Vogel RA, et al. Effect of a o ti hy pe ite os ive age o ts o o cardiovascular events in patients with coronary U isease aoci normal blood pressure: the CAMELOT stucly: a ratidomísed coutrollecl trial. JAMA; 2004, 292:2217-26. F'reeniatitle N. Cleland J. Young Mason J. 1-larrison J. Beta-blockacle after myocarclial infarction: systematic review aocI mcta regression analysis. BMW 1999, 318:1730-7.
The SOLVI) lnvestigators. Effect of enalapr ¡1 oit mor tal i ty aoci the ti evelopmen t of hear t fa u u re in asymptomatic patients with reduced lcft ventricular ejection fractions. N Engl 3 Mcd: 1992, 372:685-9 1.
MERIT-HF Study Group. Effect of metoprolol CR/XL lo chronic heart failure: Meto pro lol CR/XL Ra a do ni i se cl Intervention Trial lo Congestive Heart Failure (MERIT-I-1F). Lancet: 1999, 353:2001-6.
Messcrli FH, Grossman E, Lever AE Do thiazide diurctics confer spccific protection against strokes? Arch latero Mccl: 2003.163:2557-60. Blood Pressure Lowering Treatment Trialists' Col laboration. Effects of different hlood pressure lowering regimens on maj or cardiovascular events: results of prospectively-designed overviews of ranclomizeci trials. Lancet: 2003.362:1527-35. 1 lostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl 3 Mcd: 2001, 345:910-2.
Stergiou GS. Angiotensin receptor hiockade in the challenging era of systolic hypertension. J Hum Hypertens: 2004.18:837-47.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2021 Universidad Nacional de Córdoba
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Se permite la generación de obras derivadas siempre que no se haga con fines comerciales. Tampoco se puede utilizar la obra original con fines comerciales.
Cómo citar
